SEARCH

SEARCH BY CITATION

References

  • Baxter, L.L., and Pavan, W.J. (2003). Pmel17 expression is Mitf-dependent and reveals cranial melanoblast migration during murine development. Gene Expr. Patterns 3, 703707.
  • Baxter, L.L., Hsu, B.J., Umayam, L., Wolfsberg, T.G., Larson, D.M., Frith, M.C., Kawai, J., Hayashizaki, Y., Carninci, P., and Pavan, W.J. (2007). Informatic and genomic analysis of melanocyte cDNA libraries as a resource for the study of melanocyte development and function. Pigment Cell Res. 20, 201209.
  • Bennett, D.C. (1991). Colour genes, oncogenes and melanocyte differentiation. J. Cell Sci. 98 (Pt 2), 135139.
  • Bennett, D.C. (2008). How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res. 21, 2738.
  • Bennett, D.C., Trayner, I.D., Piao, X., Easty, D.J., Kluppel, M., Alexander, W.S., Wagner, E.F., and Bernstein, A. (1998). Recessive spotting: a linked locus that interacts with W/Kit but is not allelic. Genes Cells 3, 235244.
  • Bernex, F., De Sepulveda, P., Kress, C., Elbaz, C., Delouis, C., and Panthier, J.J. (1996). Spatial and temporal patterns of c-kit-expressing cells in WlacZ/+ and WlacZ/WlacZ mouse embryos. Development 122, 30233033.
  • Buac, K., Watkins-Chow, D.E., Loftus, S.K., Larson, D.M., Incao, A., Gibney, G., and Pavan, W.J. (2008). A Sox10 expression screen identifies an amino acid essential for Erbb3 function. PLoS Genet. 4, e1000177.
  • Budi, E.H., Patterson, L.B., and Parichy, D.M. (2008). Embryonic requirements for ErbB signaling in neural crest development and adult pigment pattern formation. Development 135, 26032614.
  • Carpenter, G. (2003). Nuclear localization and possible functions of receptor tyrosine kinases. Curr. Opin. Cell Biol. 15, 143148.
  • Carraway III, K.L., Sliwkowski, M.X., Akita, R., Platko, J.V., Guy, P.M., Nuijens, A., Diamonti, A.J., Vandlen, R.L., Cantley, L.C., and Cerione, R.A. (1994). The erbB3 gene product is a receptor for heregulin. J. Biol. Chem. 269, 1430314306.
  • Chan, C.C., Hikita, N., Dastgheib, K., Whitcup, S.M., Gery, I., and Nussenblatt, R.B. (1994). Experimental melanin-protein-induced uveitis in the Lewis rat. Immunopathologic processes. Ophthalmology 101, 12751280.
  • Chien, A.J., Moore, E.C., Lonsdorf, A.S., Kulikauskas, R.M., Rothberg, B.G., Berger, A.J., Major, M.B., Hwang, S.T., Rimm, D.L., and Moon, R.T. (2009). Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc. Natl. Acad. Sci. U S A 106, 11931198.
  • Curtin, J.A., Fridlyand, J., Kageshita, T. et al. (2005). Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 21352147.
  • Dissanayake, S.K., Olkhanud, P.B., O’connell, M.P. et al. (2008). Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res. 68, 1020510214.
  • Frogne, T., Laenkholm, A.V., Lyng, M.B., Henriksen, K.L., and Lykkesfeldt, A.E. (2009). Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res. 11, R11.
  • Guy, P.M., Platko, J.V., Cantley, L.C., Cerione, R.A., and Carraway III, K.L. (1994). Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. U S A 91, 81328136.
  • Haass, N.K., Smalley, K.S., Li, L., and Herlyn, M. (2005). Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res. 18, 150159.
  • Hoek, K.S., Schlegel, N.C., Brafford, P. et al. (2006). Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res. 19, 290302.
  • Hoek, K.S., Eichhoff, O.M., Schlegel, N.C., Dobbeling, U., Kobert, N., Schaerer, L., Hemmi, S., and Dummer, R. (2008). In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 68, 650656.
  • Horiuchi, K., Zhou, H.M., Kelly, K., Manova, K., and Blobel, C.P. (2005). Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins beta1 and beta2. Dev. Biol. 283, 459471.
  • Hou, L., and Pavan, W.J. (2008). Transcriptional and signaling regulation in neural crest stem cell-derived melanocyte development: do all roads lead to Mitf? Cell Res. 18, 11631176.
  • Hou, L., Panthier, J.J., and Arnheiter, H. (2000). Signaling and transcriptional regulation in the neural crest-derived melanocyte lineage: interactions between KIT and MITF. Development 127, 53795389.
  • Kawano, O., Sasaki, H., Endo, K., Suzuki, E., Haneda, H., Yukiue, H., Kobayashi, Y., Yano, M., and Fujii, Y. (2008). ErbB3 mRNA expression correlated with specific clinicopathologic features of Japanese lung cancers. J. Surg. Res. 146, 4348.
  • Kim, H.H., Vijapurkar, U., Hellyer, N.J., Bravo, D., and Koland, J.G. (1998). Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein. Biochem. J. 334, 189195.
  • Kim, M., Gans, J.D., Nogueira, C. et al. (2006). Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125, 12691281.
  • Kondratiev, S., Gnepp, D.R., Yakirevich, E., Sabo, E., Annino, D.J., Rebeiz, E., and Laver, N.V. (2008). Expression and prognostic role of MMP2, MMP9, MMP13, and MMP14 matrix metalloproteinases in sinonasal and oral malignant melanomas. Hum. Pathol. 39, 337343.
  • Koumakpayi, I.H., Diallo, J.S., Le Page, C., Lessard, L., Gleave, M., Begin, L.R., Mes-Masson, A.M., and Saad, F. (2006). Expression and nuclear localization of ErbB3 in prostate cancer. Clin. Cancer Res. 12, 27302737.
  • Koumakpayi, I.H., Diallo, J.S., Le Page, C., Lessard, L., Filali-Mouhim, A., Begin, L.R., Mes-Masson, A.M., and Saad, F. (2007). Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer. BJU Int. 100, 303309.
  • Levy, C., Khaled, M., and Fisher, D.E. (2006). MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol. Med. 12, 406414.
  • Lo, H.W., and Hung, M.C. (2006). Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br. J. Cancer 94, 184188.
  • Loftus, S.K., Larson, D.M., Baxter, L.L., Antonellis, A., Chen, Y., Wu, X., Jiang, Y., Bittner, M., Hammer III, J.A., and Pavan, W.J. (2002). Mutation of melanosome protein RAB38 in chocolate mice. Proc. Natl. Acad. Sci. U S A 99, 44714476.
  • Matsui, Y., Zsebo, K.M., and Hogan, B.L. (1990). Embryonic expression of a haematopoietic growth factor encoded by the Sl locus and the ligand for c-kit. Nature 347, 667669.
  • Mcgary, E.C., Lev, D.C., and Bar-Eli, M. (2002). Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol. Ther. 1, 459465.
  • Meyer, D., Yamaai, T., Garratt, A., Riethmacher-Sonnenberg, E., Kane, D., Theill, L.E., and Birchmeier, C. (1997). Isoform-specific expression and function of neuregulin. Development 124, 35753586.
  • Nakayama, A., Nguyen, M.T., Chen, C.C., Opdecamp, K., Hodgkinson, C.A., and Arnheiter, H. (1998). Mutations in microphthalmia, the mouse homolog of the human deafness gene MITF, affect neuroepithelial and neural crest-derived melanocytes differently. Mech. Dev. 70, 155166.
  • Opdecamp, K., Nakayama, A., Nguyen, M.T., Hodgkinson, C.A., Pavan, W.J., and Arnheiter, H. (1997). Melanocyte development in vivo and in neural crest cell cultures: crucial dependence on the Mitf basic-helix-loop-helix-zipper transcription factor. Development 124, 23772386.
  • Riethmacher, D., Sonnenberg-Riethmacher, E., Brinkmann, V., Yamaai, T., Lewin, G.R., and Birchmeier, C. (1997). Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature 389, 725730.
  • Scott, G.A., Mcclelland, L.A., Fricke, A.F., and Fender, A. (2009). Plexin C1, a receptor for semaphorin 7A, inactivates cofilin and is a potential tumor suppressor for melanoma progression. J. Invest. Dermatol. 129, 954963.
  • Siegfried, C.J., and Hendricks, R.L. (1994). Melanin can deplete immunosuppressive substances from the aqueous humor. Curr. Eye Res. 13, 869873.
  • Sierke, S.L., Cheng, K., Kim, H.H., and Koland, J.G. (1997). Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem. J. 322 (Pt 3), 757763.
  • Silver, D.L., Hou, L., and Pavan, W.J. (2006). The genetic regulation of pigment cell development. Adv. Exp. Med. Biol. 589, 155169.
  • Sithanandam, G., and Anderson, L.M. (2008). The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther. 15, 413448.
  • Sliwkowski, M.X., Schaefer, G., Akita, R.W., Lofgren, J.A., Fitzpatrick, V.D., Nuijens, A., Fendly, B.M., Cerione, R.A., Vandlen, R.L., and Carraway III, K.L. (1994). Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem. 269, 1466114665.
  • Stahl, J.M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J.Q., Bosenberg, M.W., Kester, M., Sandirasegarane, L., and Robertson, G.P. (2004a). Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 64, 70027010.
  • Stahl, S., Bar-Meir, E., Friedman, E., Regev, E., Orenstein, A., and Winkler, E. (2004b). Genetics in melanoma. Isr. Med. Assoc. J. 6, 774777.
  • Sviderskaya, E.V., Wakeling, W.F., and Bennett, D.C. (1995). A cloned, immortal line of murine melanoblasts inducible to differentiate to melanocytes. Development 121, 15471557.
  • Ueno, Y., Sakurai, H., Tsunoda, S., Choo, M.K., Matsuo, M., Koizumi, K., and Saiki, I. (2008). Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells. Int. J. Cancer 123, 340347.
  • Vaisanen, A., Kallioinen, M., Taskinen, P.J., and Turpeenniemi-Hujanen, T. (1998). Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J. Pathol. 186, 5158.
  • Vaisanen, A.H., Kallioinen, M., and Turpeenniemi-Hujanen, T. (2008). Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma. Hum. Pathol. 39, 377385.
  • Vance, K.W., and Goding, C.R. (2004). The transcription network regulating melanocyte development and melanoma. Pigment Cell Res. 17, 318325.
  • Weeraratna, A.T., Becker, D., Carr, K.M. et al. (2004). Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene 23, 22642274.
  • Wells, A., and Marti, U. (2002). Signalling shortcuts: cell-surface receptors in the nucleus? Nat. Rev. Mol. Cell Biol. 3, 697702.
  • Wen, D., Suggs, S.V., Karunagaran, D. et al. (1994). Structural and functional aspects of the multiplicity of Neu differentiation factors. Mol. Cell. Biol. 14, 19091919.
  • Wenandy, L., Sorensen, R.B., Svane, I.M., Thor Straten, P., and Andersen, M.H. (2008). RhoC a new target for therapeutic vaccination against metastatic cancer. Cancer Immunol. Immunother. 57, 18711878.
  • Xie, S., Luca, M., Huang, S., Gutman, M., Reich, R., Johnson, J.P., and Bar-Eli, M. (1997). Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res. 57, 22952303.